TY - JOUR
T1 - Lack of association between antiphospholipid antibodies and first- trimester spontaneous abortion
T2 - Prospective study of pregnancies detected within 21 days of conception
AU - Simpson, Joe L.
AU - Carson, Sandra A.
AU - Chesney, Carolyn
AU - Conley, Mary R.
AU - Metzger, Boyd
AU - Aarons, Jerome
AU - Holmes, Lewis B.
AU - Jovanovic-Peterson, Lois
AU - Knopp, Robert
AU - Mills, James L.
N1 - Funding Information:
Supported by grants and contracts from the National Institute of Child Health and Human Development, National Institutes of Health.
PY - 1998/5
Y1 - 1998/5
N2 - Objective: To determine the role of antiphospholipid antibodies and anticardiolipin antibodies in first-trimester losses, addressing experimental pitfalls that preclude excluding the possibility that these antibodies reflect merely the selection bias of studying couples only after they have already experienced losses. Design: Given that retrospective studies cannot exclude the possibility that such antibodies arise as a result of the fetal death, blood samples were obtained either before pregnancy or very early in pregnancy. Sera were obtained within 21 days of conception. Setting: Multicenter university-based hospitals (National Institute of Child Health and Human Development collaborative study). Patient(s): Subjects for the current study were 93 women who later experienced pregnancy loss (48 diabetic; 45 nondiabetic), matched 2:1 with 190 controls (93 diabetic and 97 nondiabetic) who subsequently had normal live-born offspring. Intervention(s): Sera from these 283 women were analyzed for antiphospholipid antibodies by enzyme immunoassay. In 260 of the 283 women (87 with pregnancy losses; 173 with live-born infants), sera were also available to perform assays for anticardiolipin antibodies by enzyme immunoassay. Main Outcome Measure(s): Pregnancy losses. Result(s): No association was observed between pregnancy loss and the presence of antiphospholipid antibodies or anticardiolipin antibodies. Levels of antiphospholipid antibodies were 6-19 PL/mL in 62.4% of the pregnancies that ended in losses and ≤20 PL/mL in 5.4%; among pregnancies resulting in live-born infants, the percentages were 56.8% and 6.8%, respectively. Of the pregnancies that ended in a loss, 5.7% had anticardiolipin antibodies ≤16 GPL/mL, compared with 5.2% of those ending in a live birth. Conclusion(s): This prospective study suggests that anticardiolipin antibodies and antiphospholipid antibodies are not associated with an increased risk for first-trimester pregnancy loss.
AB - Objective: To determine the role of antiphospholipid antibodies and anticardiolipin antibodies in first-trimester losses, addressing experimental pitfalls that preclude excluding the possibility that these antibodies reflect merely the selection bias of studying couples only after they have already experienced losses. Design: Given that retrospective studies cannot exclude the possibility that such antibodies arise as a result of the fetal death, blood samples were obtained either before pregnancy or very early in pregnancy. Sera were obtained within 21 days of conception. Setting: Multicenter university-based hospitals (National Institute of Child Health and Human Development collaborative study). Patient(s): Subjects for the current study were 93 women who later experienced pregnancy loss (48 diabetic; 45 nondiabetic), matched 2:1 with 190 controls (93 diabetic and 97 nondiabetic) who subsequently had normal live-born offspring. Intervention(s): Sera from these 283 women were analyzed for antiphospholipid antibodies by enzyme immunoassay. In 260 of the 283 women (87 with pregnancy losses; 173 with live-born infants), sera were also available to perform assays for anticardiolipin antibodies by enzyme immunoassay. Main Outcome Measure(s): Pregnancy losses. Result(s): No association was observed between pregnancy loss and the presence of antiphospholipid antibodies or anticardiolipin antibodies. Levels of antiphospholipid antibodies were 6-19 PL/mL in 62.4% of the pregnancies that ended in losses and ≤20 PL/mL in 5.4%; among pregnancies resulting in live-born infants, the percentages were 56.8% and 6.8%, respectively. Of the pregnancies that ended in a loss, 5.7% had anticardiolipin antibodies ≤16 GPL/mL, compared with 5.2% of those ending in a live birth. Conclusion(s): This prospective study suggests that anticardiolipin antibodies and antiphospholipid antibodies are not associated with an increased risk for first-trimester pregnancy loss.
KW - Anticardiolipin antibodies
KW - Antiphospholipid antibodies
KW - Cohort study design
KW - Pregnancy loss
UR - http://www.scopus.com/inward/record.url?scp=0032079461&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032079461&partnerID=8YFLogxK
U2 - 10.1016/S0015-0282(98)00054-5
DO - 10.1016/S0015-0282(98)00054-5
M3 - Article
C2 - 9591485
AN - SCOPUS:0032079461
SN - 0015-0282
VL - 69
SP - 814
EP - 820
JO - Fertility and Sterility
JF - Fertility and Sterility
IS - 5
ER -